linjc16/ctgov huggingface dataset:
Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

Study Overview
=================
Brief Summary
-----------------
Background: Sugar intake, especially in liquid, correlates with obesity. Yet, whether it is a special cause of obesity is less clear. Few experimental studies exist. Aim: To replicate the investigators' previous 4 week experiments on women with men over 8 weeks to ascertain if: they gain weight given sucrose soft drinks; mood is affected; energy intake is affected. Participants: 80 men BMI 25-35, aged 30-55. Procedure: After a week of baseline, over eight weeks single blind 40 men received soft drinks containing sucrose (1650 KJ, 97g carbohydrate per day), 40 received control drinks. A three-day food diary with mood ratings and activity levels was completed during baseline and weeks 1, 4 and 8 of the experiment. Body mass was recorded weekly with other anthropometric measures.

Official Title
-----------------
Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Dietary Supplement: Sucrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 25-35 Exclusion Criteria: Diabetes, other health problems, medication, dislike of soft drinks

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sucrose<br>Sucrose: 1l sucrose sweetened soft drink per day for 8 weeks (1650 KJ, 97g carbohydrate per day) as 4 25cl drinks | Dietary Supplement: Sucrose<br>* Sucrose sweetened soft drinks<br>* Other names: Aspartame sweetened soft drinks as comparator;|
| Placebo Comparator: Aspartame<br>Aspartame: 1l aspartame sweetened soft drink per day for 8 weeks as 4 25cl drinks | Dietary Supplement: Sucrose<br>* Sucrose sweetened soft drinks<br>* Other names: Aspartame sweetened soft drinks as comparator;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Mass | Do participants gain weight? | Eight Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily energy intake assessed by free-living unweighed food diary | Do participants eat less to compensate for added sucrose? | Eight Weeks | 
| Mood assessed using 10 rating scales | Are there changes in rated mood during sucrose supplementation? | Eight Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sucrose, Sugar, Carbohydrate, Weight gain, men
Microalbuminuria in Children With and Without Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to learn more about Microalbuminuria in children with and without diabetes. Albumin is a protein that may be excreted in the urine. In some conditions, like kidney problems or diabetes, the amount of albumin in the urine increases. The purpose of this study is to measure concentration of albumin in the urine of diabetic children and compare to healthy children.

Detailed Description
-----------------
Diabetic nephropathy is a known cause of significant morbidity and mortality in adult patients with diabetes. Microalbuminuria (MA) is predictive of future diabetic nephropathy (DN) in adult patients with diabetes mellitus (DM). This link between MA levels and DN allows patients to receive timely interventions. The predictive value of MA for DN in children with DM, however, is not well established. Most studies looking at this association in children have only been forced to use adult MA values. Children, particularly adolescents, are known to have different normal values for 24-hour total protein excretion compared to adults and it may be that they also have different normal levels of MA. Little literature exists on normal levels of 24 hr MA in healthy children and in children with diabetes. In this study, we seek to define the range of MA levels that falls between the 2.5 and 97.5 percentiles for children with and without DM. Once these values are established, we will have a foundation for further studies to define which, if any, MA values are predictive of DN in children. If we can establish a MA level which is predictive of DN in children, it will allow physicians to direct medical intervention at those most likely to benefit while protecting others from unnecessary medications, procedures, and risks.

Official Title
-----------------
Microalbuminuria in Children With and Without Diabetes

Conditions
-----------------
Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children 6 to 18 Diabetic children 6 to 18 Exclusion Criteria: kidney disease abnormal body temperature history of documented urinary tract infection metabolic disease other than diabetes mellitus circulatory disease liver disease strenuous exercise in prior 24 hours nocturnal enuresis

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment

Study Overview
=================
Brief Summary
-----------------
The protein composition of HDL is complicated. The investigators have identified 40 distinct proteins associated with HDL by proteomics technology, and these proteins have been confirmed to be related to the function of anti-inflammation, anti-oxidation, improvement of endothelial function, inhibition of thrombosis and so on. And the investigators also found that the levels of some proteins in HDL changed in patients with coronary heart disease, compared with the healthy control group. So, this study is to conduct in the two following aspects: enlarge the sample size to verify the preliminary results to find new research ideas of pathogenesis and biomarkers for coronary heart disease; and study the changes of HDL protein composition in patients with coronary heart disease before and after statins treatment using proteomics technology in order to find the mechanism of statins pleiotropic effects and indicators for evaluating the treatment effectiveness.

Official Title
-----------------
Phase 1 Study of Coronary Heart Disease Proteomics Research

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Angiographic evidence of coronary artery disease, and no lipid-lowering therapy in the past 2 weeks for treatment group; Exclusion Criteria: Use of potent lipid-lowering therapy for more than 2 weeks; myocardial infarction or percutaneous coronary intervention in the past 6 months; severe congestive heart failure, valvular heart disease and other non-coronary heart disease cardiovascular disease; liver or renal dysfunction; connective tissue disease; infection, Malignancy; and other conditions that physicians considered inappropriate to the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| coronary heart disease<br> | |
| healthy control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differential Proteins and the levels of Differential Proteins |  | up to 3 years |
Pilot Study for Imaging of the Esophagus Using Tethered Capsule OCT Endomicroscopy With Distal Scanning

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test feasibility of a redesigned tethered capsule catheter that contains an integrated micro-motor. Investigators will be testing imaging of this new technology in healthy volunteers.

Detailed Description
-----------------
10 healthy volunteers will be enrolled and asked to swallow the Distal Scanning Capsule. The subjects will be awake and un-sedated. The capsule is attached to a string like tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus using natural propulsive force called peristalsis. As the capsule progresses through the esophagus, multiple images of the esophagus are acquired in real time to be analyzed later.

Official Title
-----------------
Pilot Study for Imaging of the Esophagus Using Tethered Capsule OCT Endomicroscopy With Distal Scanning

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: OFDI capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must be over the age of 18 Subjects must be able to give informed consent Subjects must have no solid food for 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure. Exclusion Criteria: Subjects with the inability to swallow pills and capsules. Esophageal fistula and/or esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule. Subjects who have a bleeding disorder and are currently on anti-coagulants.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OFDI capsule imaging<br>Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system. | Device: OFDI capsule<br>* Imaging of esophagus using OFDI capsule and system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants For Whom Good Quality Images Were Recorded After Swallowing The OFDI Capsule | An investigator to assess the quality of the recorded images obtained with each exam after imaging has been completed | Approximate 20 minute visit (5 min image acquisition) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy Volunteers
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.

Official Title
-----------------
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia

Conditions
-----------------
Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Blast Crisis, Leukemia, Lymphocytic

Intervention / Treatment
-----------------
* Drug: Farnesyl Protein Transferase Inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. Life expectancy of 12 weeks or greater. ECOG Performance Status less than or equal to 2. Meets protocol requirements for specified laboratory values. No manifestations of a malabsorption syndrome. Exclusion Criteria: Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. Patients who have received investigational therapy of any type within 30 days prior to administration.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Farnesyl Protein Transferase Inhibitor|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Leukemia, Lymphocytic
Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?

Study Overview
=================
Brief Summary
-----------------
Evaluate the utility/safety of an FDA-approved tissue sealing device during radical cystectomy as compared to an FDA-approved stapling device.

Official Title
-----------------
Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?

Conditions
-----------------
Bladder Cancer, Hemostasis

Intervention / Treatment
-----------------
* Device: Stapling device during radical cystectomy
* Device: Ligasure tissue sealing device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Muscle invasive bladder cancer Male/Female gender Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Stapling device<br>Efficacy of stapling device during radical cystectomy | Device: Stapling device during radical cystectomy<br>* Hemostasis<br>* Other names: Ethicon articulating stapler;|
| Active Comparator: Ligasure Device<br>Efficacy of ligasure tissue sealing device during radical cystectomy | Device: Ligasure tissue sealing device<br>* Efficacy of tissue sealing device during hemostasis<br>* Other names: Tissue sealing device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimated Blood Loss |  | Perioperative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operating Room Time in Minutes |  | Intraoperative time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tissue sealing device, Articulating stapling device, Radical cystectomy
Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction

Study Overview
=================
Brief Summary
-----------------
Femoral nerve block using 0.25% bupivacaine or 0.5% bupivacaine provides a longer time for analgesia after Anterior Cruciate Ligament (ACL) reconstruction.

Official Title
-----------------
Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction

Conditions
-----------------
Analgesia After ACL Reconstruction

Intervention / Treatment
-----------------
* Drug: 0.25% Bupivacaine
* Drug: 0.5% Bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for ACL reconstruction ASA physical status I-II Body weight > or = 50 kg. Exclusion Criteria: Patients with redo ACL reconstruction Contraindication to neuraxial block allergy to local anesthetics, sulfa, NSAIDs, morphine, paracetamol Patients with communication problem

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 0.25% bupivacaine<br>femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine | Drug: 0.25% Bupivacaine<br>* Femoral nerve block using 0.25% versus 0.5% bupivacaine<br>* Other names: marcaine;|
| Active Comparator: 0.5% bupivacaine<br>femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine | Drug: 0.5% Bupivacaine<br>* Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction<br>* Other names: marcaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to first analgesic requirement |  | 48 hr | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain score scale |  | 48 hr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
femoral nerve block
Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether blockade of the saphenous nerve can provide the same degree of analgesia postoperatively for ACLS as a femoral nerve block without resulting motor blockade enhancing shortening of hospital stay en functional outcome.

Official Title
-----------------
Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery

Conditions
-----------------
Postoperative Analgesia for Anterior Cruciate Ligament Surgery of the Knee

Intervention / Treatment
-----------------
* Procedure: Saphenous nerve blockade
* Procedure: Femoral nerve blockade


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-65 years ASA status I - III rupture of the anterior cruciate ligament. Exclusion Criteria: contraindication for regional anesthesia allergy against local anesthetics BMI > 35 pre-existing diagnosed neuropathy of the operated leg ingestion of strong opioids pregnancy or breastfeeding status History of significant cardiovascular disease (MI, CVA, peripheral vascular disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Saphenous nerve blockade<br>Experimental treatment 15 mL of levobupivacaine 0.5% | Procedure: Saphenous nerve blockade<br> <br> |
| Active Comparator: Femoral nerve blockade<br>Standard treatment 15 mL of levobupivacaine 0.5% | Procedure: Femoral nerve blockade<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Readiness to discharge from day-care center in hours according to Post-Anesthetic Discharge Scoring System (PADSS).[ |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Motor block |  | 2 days | 
| Pain (VAS) |  | 2 days | 
| Sensory blockade extent |  | 1 Day | 
| Time to rescue analgesic and post operative opioid consumption |  | 1 Day | 
| Overall Benefit of Analgesia Score (OBAS) |  | 6 weeks | 
| SF-12 score |  | 12 weeks | 
| KOOS-score |  | 12 weeks | 
| IKDC-score |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Day care, Saphenous nerve block, Adductor canal block, Anterior cruciate ligament, Pain management
Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University.

Study Overview
=================
Brief Summary
-----------------
Low bone mineral density (BMD) has recently increased among young women. Soy Isoflavone as a food supplement, has been found to have potent effect on bone health in postmenopausal women. However, the effect of soy isoflavone on pre-menopausal is not well understood. This research is done to examine the effect of soy isoflavones on BMD among young university female students.

Official Title
-----------------
Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University.

Conditions
-----------------
Soy Isoflavone Effect, Bone Density, Low, Bone Density Increased

Intervention / Treatment
-----------------
* Dietary Supplement: Soy Isoflavone supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female University students aged between 18-25 years Exclusion Criteria: Study participants who use medications and suffer from diseases that may interfere or effect on BMD, use calcium and vitamin D supplements and who suffer from glucose 6 phosphate deficiency (G6PD) were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Pre-post Quasi experimental study design.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>In four weeks of intervention study the participants instructed to receive (60 mg) of soy-isoflavone supplement per day, after this period the Bone Mineral Density was assessed by Dual X-ray Absorptiometry scan to evaluate the effect of soy-isoflavone supplement on Bone mineral density. | Dietary Supplement: Soy Isoflavone supplement<br>* Participants received 60 mg of soy-isoflavone supplement per day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone Mineral Density (BMD) |  | 4 weeks |